homepage-top-section

Specialist HIV company ViiV Healthcare has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) to expand the use of Cabenuva. Cabenuva

Pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for priority review for TicoVac, a tick-borne encephalitis

AstraZeneca has voluntarily withdrawn the Imfinzi (durvalumab) indication for adult patients who received treatment earlier in the US for locally advanced or metastatic bladder cancer. The company has

Biopharmaceutical company Dynavax Technologies (DVAX) has secured marketing authorisation from the European Commission (EC) for Heplisav B, a two-dose adult hepatitis B adjuvanted vaccine. The vaccine is used

Fast Track Designation is a process for facilitating the development and expediting the review of drugs to treat serious medical conditions. The novel and investigational factor VIII therapy

Pfizer and BioNTech have entered into an agreement with the European Commission (EC) to supply an additional 200 million doses of their Covid-19 vaccine. The deal also includes

Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19

South Korean biopharmaceutical company Celltrion Healthcare has secured European Commission (EC) marketing authorisation for the sale of Yuflyma (CT-P17) for the treatment of multiple chronic inflammatory diseases. Yuflyma

The three partner sites in London, Southampton and Bristol. Building on earlier studies of the vaccine that have shown that it is safe, produces strong immune system responses and